BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 7945441)

  • 21. Targets and markers of selective action of tiazofurin.
    Weber G; Natsumeda Y; Pillwein K
    Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside.
    Jäger W; Salamon A; Szekeres T
    Curr Med Chem; 2002 Apr; 9(7):781-6. PubMed ID: 11966442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside.
    Damaraju VL; Visser F; Zhang J; Mowles D; Ng AM; Young JD; Jayaram HN; Cass CE
    Mol Pharmacol; 2005 Jan; 67(1):273-9. PubMed ID: 15486050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxicity of tiazofurin and its arabinose and xylose analogues in K562 cells.
    Zhen W; Jayaram HN; Marquez VE; Goldstein BM; Cooney DA; Weber G
    Biochem Biophys Res Commun; 1991 Oct; 180(2):933-8. PubMed ID: 1683233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
    Jayaram HN; Zhen W; Gharehbaghi K
    Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate dehydrogenase induces transferrin receptors in cancer cells.
    Szekeres T; Sedlak J; Novotny L
    Curr Med Chem; 2002 Apr; 9(7):759-64. PubMed ID: 11966439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IMP dehydrogenase and action of antimetabolites in human cultured blast cells.
    Yamada Y; Goto H; Yoshino M; Ogasawara N
    Biochim Biophys Acta; 1990 Mar; 1051(3):209-14. PubMed ID: 1968764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of enzymic programs and nucleotide pattern in cancer cells by acivicin and tiazofurin.
    Weber G; Natsumeda Y; Lui MS; Faderan MA; Liepnieks JJ; Elliott WL
    Adv Enzyme Regul; 1984; 22():69-93. PubMed ID: 6206692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
    Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
    J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase.
    Yamada Y; Natsumeda Y; Weber G
    Biochemistry; 1988 Mar; 27(6):2193-6. PubMed ID: 2897864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicity and efficacy of benzamide riboside in cancer chemotherapy models.
    Jayaram HN; Yalowitz JA; Arguello F; Greene JF
    Curr Med Chem; 2002 Apr; 9(7):787-92. PubMed ID: 11966443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses.
    Huggins JW; Robins RK; Canonico PG
    Antimicrob Agents Chemother; 1984 Oct; 26(4):476-80. PubMed ID: 6151377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
    Wright DG; Boosalis M; Malek K; Waraska K
    Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical mechanisms of resistance to tiazofurin.
    Jayaram HN
    Adv Enzyme Regul; 1985; 24():67-89. PubMed ID: 3835825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in vitro studies of Tiazofurin and a selenazole analog.
    Streeter DG; Robins RK
    Biochem Biophys Res Commun; 1983 Sep; 115(2):544-50. PubMed ID: 6138036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5'-phosphate dehydrogenase.
    Sokoloski JA; Blair OC; Sartorelli AC
    Cancer Res; 1986 May; 46(5):2314-9. PubMed ID: 2870796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytotoxicity and cellular differentiation activity of methylenebis(phosphonate) analogs of tiazofurin and mycophenolic acid adenine dinucleotide in human cancer cell lines.
    Yalowitz JA; Pankiewicz K; Patterson SE; Jayaram HN
    Cancer Lett; 2002 Jul; 181(1):31-8. PubMed ID: 12430176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
    Sokoloski JA; Sartorelli AC
    Mol Pharmacol; 1985 Dec; 28(6):567-73. PubMed ID: 2867464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
    Weber G; Jayaram HN; Lapis E; Natsumeda Y; Yamada Y; Yamaji Y; Tricot GJ; Hoffman R
    Adv Enzyme Regul; 1988; 27():405-33. PubMed ID: 2907968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).
    Ahluwalia GS; Cooney DA; Marquez VE; Jayaram HN; Johns DG
    Biochem Pharmacol; 1986 Nov; 35(21):3783-90. PubMed ID: 2877671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.